Louis E, Schreiber S, Panaccione R,; INSPIRE and COMMAND Study Group. Risankizumab for ulcerative colitis: Two randomized clinical trials. JAMA. 2024; 332 (11): 881-897. doi: 10.1001/jama.2024.12414 39037800
Le Berre C, Honap S, Peyrin-Biroulet L. Ulcerative colitis. Lancet. 2023; 402 (10401): 571-584. doi: 10.1016/S0140-6736(23)00966-2 37573077
Ng SC, Shi HY, Hamidi N, Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: A systematic review of population-based studies. Lancet. 2017; 390 (10114): 2769-2778. doi: 10.1016/S0140-6736(17)32448-0 29050646
Lewis JD, Parlett LE, Jonsson Funk ML, Incidence, prevalence, and racial and ethnic distribution of inflammatory bowel disease in the United States. Gastroenterology. 2023; 165 (5): 1197-1205.e2. doi: 10.1053/j.gastro.2023.07.003 37481117
Cohen NA, Silfen A, Rubin DT. Inclusion of under-represented racial and ethnic minorities in randomized clinical trials for inflammatory bowel disease. Gastroenterology. 2022; 162 (1): 17-21. doi: 10.1053/j.gastro.2021.09.035 34562464
Thakre N, Goebel A, Winzenborg I, Population pharmacokinetic and exposure-response modeling to inform risankizumab dose selection in patients with ulcerative colitis. Clin Pharmacol Ther. 2024; 116 (3): 847-857. doi: 10.1002/cpt.3330 38863178
